SCHEMBL10107682

SCHEMBL10107682

CC(N)c1c(-c2cc(F)cc(F)c2)c(=O)c2cc(F)ccc2n1C

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.56
ATM Q13315 1/20 0.40
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
HCRTR1 O43613 1/20 0.35
HSP90AA1 P07900 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPK14 Q16539 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
PER2 O15055 1/20 0.32
CRY2 Q49AN0 1/20 0.32
SRC P12931 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL890583 0.87 PIK3CD (0.53) PIK3CDATMKMT2AMEN1HCRTR1
SCHEMBL890802 0.81 PIK3CD (0.48) PIK3CDATMKMT2AMEN1HCRTR1
SCHEMBL890554 0.76 PIK3CD (0.43) PIK3CDATMKMT2AMEN1HCRTR1
SCHEMBL890518 0.73 PIK3CD (1.00) PIK3CD
SCHEMBL28094615 0.72 ATM (0.44) PIK3CDATMKMT2AMEN1HCRTR1
SCHEMBL13925420 0.70 ATM (0.67) ATMKMT2AMEN1HCRTR1HSP90AA1
SCHEMBL10120345 0.69 PIK3CD (0.55) PIK3CDHTR2AHTR2CKMT2AMEN1
SCHEMBL8140534 0.65 ATM (0.53) ATMKMT2AMEN1HCRTR1HSP90AA1
SCHEMBL22016488 0.65 ATM (0.41) ATMKMT2AMEN1HCRTR1HSP90AA1
SCHEMBL17718404 0.65 DPP4 (0.45) KMT2AHCRTR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 24/4885ATM 639/4885HTR2A 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.